|  |
| --- |
|  |
| Book Name: | [**Medical Science: Trends and Innovations**](https://www.bookpi.org/bookstore/product/medical-science-trends-and-innovations-vol-1/) |
| Manuscript Number: | **Ms\_BPR\_4264** |
| Title of the Manuscript:  | **Successful Use of Nivolumab in a Patient with Head and Neck Cancer After Allogeneic Bone Marrow Transplantation** |
| Type of the Article | **Book Chapter** |

|  |
| --- |
| PART 1: Comments |
|  | Reviewer’s comment | Author’s Feedback *(Please correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)* |
| **Please write a few sentences regarding the importance of this manuscript for the scientific community. A minimum of 3-4 sentences may be required for this part.** | **The article demonstrates a case study of a successful treatment of a patient with buccal malignant tumor cancer with mandibular destruction and hemoblastosis with bone marrow transplantation. This combination of two cancers is rare. Importantly, the patient received immunosuppressors in addition to polychemotherapy and bone marrow transplantation. Therefore, it was very important to understand how immunosuppressive therapy may affect the efficacy of immunotherapy with nivolumab for cheek cancer. The observation showed that the combined use of immunosuppression and an immune checkpoint inhibitor with good outcome is possible. This observation will be very useful for oncologists and chemotherapists.** |  |
| **Is the title of the article suitable?****(If not please suggest an alternative title)** | **Yes** |  |
| Is the abstract of the article comprehensive? Do you suggest the addition (or deletion) of some points in this section? Please write your suggestions here. | **Yes** |  |
| **Is the manuscript scientifically, correct? Please write here.**  | **The case described is rare and demonstrates scientifically the feasibility of immunosuppressors and immune checkpoint inhibitors** |  |
| **Are the references sufficient and recent? If you have suggestions of additional references, please mention them in the review form.****-** | **There are many references to articles that describe the use of nivolumab after stem cell transplantation, which is not described in this article. Therefore references #2,4,5,8,9,21,29,29,30,33,35,37,39,40,46,47 can be excluded** |  |
| Is the language/English quality of the article suitable for scholarly communications? | Appropriate |  |
| Optional/General comments | Given the interesting and rare case of an observational study with a good treatment outcome, the article can be recommended for publication |  |

|  |
| --- |
| **PART 2:**  |
|  | **Reviewer’s comment** | **Author’s comment** *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)* |
| **Are there ethical issues in this manuscript?**  | *(If yes, Kindly please write down the ethical issues here in details)* |  |

|  |
| --- |
| **Reviewer Details:** |
| Name: | **Aliaksandr Prokharau** |
| Department, University & Country | **Belarusian State Medical University, Belarus** |